INTRODUCTION {#s1}
============

Nowadays, Barcelona Clinic Liver Cancer (BCLC) stage is the sole system approved by the European Association for Study of the Liver (EASL) and American Association for the Study of Liver Disease (AASLD) guidelines for the prognostic classification and treatment selection of hepatocellular carcinoma (HCC) \[[@R1]-[@R2]\]. According to this staging system, hepatic resection should be recommended in the BCLC stage 0 or A HCC with a single nodule (i.e., "the patients do not have liver cirrhosis or have liver cirrhosis but still have well preserved liver function, normal bilirubin and hepatic vein pressure gradient \< 10 mmHg"), and transarterial chemoembolization (TACE) should be recommended in the BCLC stage B HCC (i.e., "the patients have large/multifocal HCC but without vascular invasion or extrahepatic spread").

Recently, based on the real-world data, several large scale studies suggested that hepatic resection might be also appropriate in HCC cases beyond the BCLC stage A. First, Farinati et al. analyzed the treatment selection and prognosis of 405 HCC cases in the BCLC stage B who were enrolled between 1986 and 2008 by the Italian Liver Cancer group \[[@R3]\]. Only 40% of HCC cases in the BCLC stage B underwent TACE. However, TACE achieved a significantly shorter survival time than hepatic resection in such patients (median: 27 months versus 37 months). Second, Vitale et al. analyzed the outcomes of 2090 HCC cases in the different BCLC stages who were enrolled between 2000 and 2012 by the Italian Liver Cancer group \[[@R4]\]. In the BCLC stages 0, A, and B, the net survival benefit of hepatic resection over non-surgical treatments was statistically significant. Third, Roayaie et al. analyzed the survival of 8,656 cases diagnosed with HCC between 2005 and 2011 in BRIDGE study \[[@R5]\]. Hepatic resection not only achieved a significantly better survival than other treatments in ideal candidates for resection, but also achieved a significantly better survival than TACE in non-ideal candidates for resection.

Herein, we conducted a systematic review and meta-analysis of available literatures to clarify the survival benefits of hepatic resection over TACE in HCC patients.

RESULTS {#s2}
=======

Systematic review {#s2_1}
-----------------

Overall, 2028 papers were initially retrieved via the three major databases, including 1219 papers in PubMed, 758 in EMBASE, and 51 in Cochrane library databases. One eligible paper was also manually identified. Among them, 50 papers were included in the systematic review (Figure [1](#F1){ref-type="fig"}) \[[@R6]-[@R55]\]. The study characteristics were summarized in Table [1](#T1){ref-type="table"}. They were performed in Australia (n=1), Canada (n=1), China (n=18), Germany (n=7), India (n=1), Italy (n=5), Japan (n=6), Portugal (n=1), South Korea (n=8), Spain (n=1), and USA (n=1). The overall conclusions of every included study were summarized as follows: 1) the survival benefit of hepatic resection was statistically significant in 29 studies \[[@R7]-[@R8], [@R11], [@R16], [@R18]-[@R19], [@R23]-[@R24], [@R26], [@R28]-[@R29], [@R33]-[@R34], [@R36], [@R38], [@R40]-[@R41], [@R45]-[@R55]\]; 2) the survival was statistically similar between the two groups in 7 studies \[[@R12], [@R15], [@R20]-[@R22], [@R27], [@R30], [@R43]\]; and 3) the statistical difference was not reported in 14 studies \[[@R6], [@R9]-[@R10], [@R13]-[@R14], [@R17], [@R25], [@R31]-[@R32], [@R35], [@R37], [@R39], [@R42], [@R44]\]. The patients\' characteristics and survival data of every study were shown in [Supplementary Table 1](#SD2){ref-type="supplementary-material"}. The eligibility criteria of every included study were shown in [Supplementary Table 2](#SD3){ref-type="supplementary-material"}. The criteria for treatment selection were shown in [Supplementary Table 3](#SD4){ref-type="supplementary-material"}. Only one study was of high quality, 15 studies were of moderate quality, and 34 studies were of low quality ([Supplementary Table 4](#SD5){ref-type="supplementary-material"}).

![Flowchart of study inclusion](oncotarget-06-18715-g001){#F1}

###### Study characteristics: An overview of included studies

  First author, Journal (Year)                                          Publication forms                        Region         Study design                                                                   Period            Follow-up time                                                                                          Target population                                                                                                                    Survival benefits (statistical significance)
  --------------------------------------------------------------------- ---------------------------------------- -------------- ------------------------------------------------------------------------------ ----------------- ------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------
  Cheng, Zhonghua Zhong Liu Za Zhi (2005)                               Full text                                China          Retrospective cohort study                                                     2000.1-2003.1     NA                                                                                                      HCC with PVTT                                                                                                                        NA.
  Choi, World J Gastroenterol (2013)                                    Full text                                South Korea    Retrospective cohort study                                                     2003.1-2008.12    Median (range):38.6 (1-94) months in resection group                                                    HCC 2-3 nodules, no vascular invasion, tumor diameter ≤5cm, Child-Pugh class A                                                       Favor hepatic resection (significant).
  Ciria, J Hepatol (2014)                                               Abstract                                 Spain          Retrospective cohort study                                                     2006-2012         Median:20.5 months in all patients                                                                      BCLC stage B HCC                                                                                                                     Favor hepatic resection (significant).
  Colella, Transpl Int (1998)                                           Full text                                Italy          Retrospective cohort study                                                     1989.1-1997.6     Median:43 months in all patients                                                                        HCC without extrahepatic spread                                                                                                      NA.
  El-Serag, J Hepatol (2006)                                            Full text                                USA            Population-based study                                                         1992-1999         NA                                                                                                      Medicare-enrolled patients with HCC in SEER registries (≥65 years old; \<65 years old and disable or with end stage renal disease)   NA.
  Fan, Eur J Surg Oncol (2014)                                          Full text                                China Taiwan   Retrospective cohort study                                                     2007.1-2012.12    Mean (range):19.5 (0-67) months in all patients                                                         Aged ≥70 years, large HCCs ≥5 cm                                                                                                     Favor hepatic resection (significant).
  Gerunda, Liver Transpl (2000)                                         Full text                                Italy          Prospective cohort study                                                       1988-1997.12      Mean:4.2±1.7 year in liver surgery group;NA in TACE group                                               Child-Pugh A or B; TNM stage I or II; \<3-5cm or \<3 nodules; no PVTT; no extrahepatic diseases                                      Statistically similar.
  Guglielmi, HPB (2011)                                                 Abstract                                 Italy          Retrospective cohort study                                                     1991-2009         NA                                                                                                      HCC with cirrhosis                                                                                                                   NA.
  Guo, Ann Surg Oncol (2014)                                            Full text                                China          Propensity score analysis                                                      2003.3-2008.3     Before propensity-score matching: median: 35.0 months in resection group; 20.8 months in TACE group     BCLC stage A HCC, Child-Pugh class A                                                                                                 NA.
  Hasse, Langenbecks Archiv für Chirurgie (1996)                        Full text                                Germany        Prospective cohort study                                                       1990.1-1996.1     NA                                                                                                      Stage pT3 or pT4 HCC                                                                                                                 Statistically similar.
  Helmberger, Digestion (2007)                                          Full text                                Germany        Retrospective cohort study                                                     1995-2006         NA                                                                                                      HCC with VISUM stage 1                                                                                                               Favor hepatic resection (significant).
  Herold, Liver (2002)                                                  Full text                                Germany        Retrospective cohort study                                                     1988.1-1999.7     Mean (range):20 (0-119) months in all patients                                                          Unselected HCC                                                                                                                       NA.
  Ho, Ann Surg Oncol (2009)                                             Full text                                China Taiwan   Retrospective cohort study                                                     1981.1-2000.6     Mean (range):20.2 (1-247.8) months                                                                      Multiple HCC                                                                                                                         Favor hepatic resection (significant).
  Hsu CY, Ann Surg Oncol (2012)                                         Full text                                China Taiwan   Propensity score analysis                                                      2002.1-2010.10    Mean: 18±16 months                                                                                      HCC beyond the Milan criteria                                                                                                        Favor hepatic resection (significant).
  Hsu KF, Eur J Radiol (2012)                                           Full text                                China Taiwan   Retrospective cohort study                                                     2001.1-2007.12    Mean:46.7±24.6 months in resection group;40.8±19.8 months in TACE group                                 Resectable early-stage HCC and Child-Pugh class A (BCLC stage A)                                                                     Statistically similar.
  Huang, EJGH (1999)                                                    Full text                                China Taiwan   Cohort study                                                                   1984-1993         NA                                                                                                      Total: Resectable HCC, well-compensated liver function, tumor localized to a single lobe                                             Statistically similar.
  Subgroup: age \>70 years                                              Statistically similar.                                                                                                                                                                                                                                                                                                                                                                                
  Jianyong, Medicine (2014)                                             Full text                                China          Retrospective cohort study                                                     2002.7-2008.11    NA                                                                                                      Total: BCLC stage B HCC                                                                                                              Statistically similar.
  Subgroup: 1 lesion of \>5 cm in diameter                              Favor hepatic resection (significant).                                                                                                                                                                                                                                                                                                                                                                
  Subgroup: 2-3 lesions (at least 1 lesion was \>3 cm in diameter)      Favor hepatic resection (significant).                                                                                                                                                                                                                                                                                                                                                                
  Subgroup: \>3 lesions of any diameter                                 Statistically similar.                                                                                                                                                                                                                                                                                                                                                                                
  Jin, J Gastrointest Surg (2014)                                       Full text                                South Korea    Retrospective cohort study                                                     1998.1-2013.4     Mean (range):18 (0.1-136) months                                                                        BCLC stage A HCC, solitary, large (\>5 cm)                                                                                           Favor hepatic resection (significant).
  Kang, Hepatol Int (2010)                                              Abstract                                 South Korea    Retrospective cohort study                                                     2003.1-2007.12    NA                                                                                                      Single HCC \<3 cm                                                                                                                    Favor hepatic resection (significant).
  Kirchner, Transplant Int (2011)                                       Abstract                                 Germany        Retrospective cohort study                                                     1993.3-2006.11    Mean:26.7±30.7 months                                                                                   Unselected HCC                                                                                                                       NA.
  Lee JM, Hepatol Int (2014)                                            Abstract                                 South Korea    Cohort study                                                                   2000.1-2011.12    NA                                                                                                      HCC with PVTT                                                                                                                        Favor hepatic resection (significant).
  Lee YB, J Hepatol (2014)                                              Abstract                                 South Korea    Propensity score analysis                                                      NA                NA                                                                                                      Resectable large solitary HCC                                                                                                        Statistically similar.
  Lin, World J Surg (2010)                                              Full text                                China Taiwan   Retrospective cohort study                                                     2001.2-2007.12    NA                                                                                                      HCC, BCLC stage B, Child-Pugh A                                                                                                      Favor hepatic resection (significant).
  Liu, Ann Surg Oncol (2014)                                            Full text                                China Taiwan   Propensity score analysis                                                      2002.2-2012.12    Mean:23±22months                                                                                        HCC, BCLC stage C, PVTT                                                                                                              Favor hepatic resection (significant).
  Luo, Radiology (2011)                                                 Full text                                China          Prospective cohort study                                                       2004.1-2006.12    NA                                                                                                      Total: Large (≥5 cm), multiple, and resectable HCC                                                                                   Statistically similar.
  Subgroup: 5-10 cm                                                     Statistically similar.                                                                                                                                                                                                                                                                                                                                                                                
  Subgroup: \>10 cm                                                     Statistically similar.                                                                                                                                                                                                                                                                                                                                                                                
  Markovic, J Hepatol (1998)                                            Full text                                Italy          Prospective cohort study                                                       1988.1-1993.12    Mean (range):40 (12-60) months                                                                          Unselected HCC (divided according to the Okuda stage and Child-Pugh class)                                                           NA.
  Martins, Liver Int (2006)                                             Full text                                Portugal       Retrospective cohort study                                                     1993.1-2003.12    Mean (range):66±11 (22-92) years                                                                        Unselected HCC                                                                                                                       NA.
  Min, JGH (2014)                                                       Full text                                South Korea    Propensity score analysis                                                      2000-2009         Median (range):14.5 (0-103) months                                                                      Huge HCC (≥10 cm in diameter)                                                                                                        Favor hepatic resection (significant).
  Nagashima, Int J Oncol (1999)                                         Full text                                Japan          Retrospective cohort study                                                     1989.1-1996.6     NA                                                                                                      Curatively unresectable intrahepatic multiple HCC with the main tumor ≥30 mm in size                                                 Favor hepatic resection (significant).
  Obed, Langenbecks Arch Surg (2008)                                    Full text                                Germany        Retrospective cohort study                                                     1995-2000         Median (range):200 (16-2054) days in TACE group;399 (11-2220) days in resection group                   Unselected HCC (divided according to UICC stage)                                                                                     NA.
  Park, J Gastroenterol Hepatol (2008)                                  Full text                                South Korea    Prospective cohort study                                                       2000.11-2003.12   Median:14.4 months                                                                                      Subgroup: Child-Pugh class A; modified UICC stage I or II                                                                            Favor hepatic resection (significant).
  Subgroup: Child-Pugh class A; modified UICC stage III                 Favor hepatic resection (significant).                                                                                                                                                                                                                                                                                                                                                                
  Paul, Oncology (2009)                                                 Full text                                India          Retrospective cohort study (1990-2000), prospective cohort study (2001-2005)   1990-2005         Mean (median):7.4±10.3 (3) months                                                                       Unselected HCC                                                                                                                       NA.
  Peng, Cancer (2012)                                                   Full text                                China          Retrospective case-control study                                               2002.12-2007.12   Mean (range):16.3±1.12 (2.0-83.0) months in resection group;12.1±0.56 (2.0-53.0) months in TACE group   Total: Resectable HCC with PVTT                                                                                                      Favor hepatic resection (significant).
  Subgroup: Resectable HCC with type I PVTT                             Favor hepatic resection (significant).                                                                                                                                                                                                                                                                                                                                                                
  Subgroup: Resectable HCC with type II PVTT                            Favor hepatic resection (significant).                                                                                                                                                                                                                                                                                                                                                                
  Subgroup: Resectable HCC with type III PVTT                           Statistically similar.                                                                                                                                                                                                                                                                                                                                                                                
  Subgroup: Resectable HCC with type IV PVTT                            Statistically similar.                                                                                                                                                                                                                                                                                                                                                                                
  Subgroup: Resectable HCC with PVTT; tumor size ≤5 cm                  Statistically similar.                                                                                                                                                                                                                                                                                                                                                                                
  Subgroup: Resectable HCC with PVTT; tumor size \>5 cm                 Favor hepatic resection (significant).                                                                                                                                                                                                                                                                                                                                                                
  Subgroup: Resectable HCC with PVTT; single tumor                      Favor hepatic resection (significant).                                                                                                                                                                                                                                                                                                                                                                
  Subgroup: Resectable HCC with PVTT; multiple tumor                    Statistically similar.                                                                                                                                                                                                                                                                                                                                                                                
  Perry, Liver Int (2007)                                               Full text                                Australia      Prospective cohort study                                                       Since 1998        Median:33 months for survivors;9 months for patients who died                                           Unselected HCC                                                                                                                       NA.
  Sako, Anticancer Research (2003)                                      Full text                                Japan          Retrospective cohort study                                                     1993.4-2001.10    Mean (range):4.2 (0.3-10.8) years in all patients                                                       HCV-related, single, small HCC                                                                                                       Favor hepatic resection (significant).
  Sasaki, J Hepatobiliary Pancreat Surg (1998)                          Full text                                Japan          Retrospective cohort study                                                     1980.1-1994.4     NA                                                                                                      Total: unselected HCC                                                                                                                Favor hepatic resection (significant).
  Subgroup: Liver Cancer Study Group of Japan stage I HCC               Statistically similar.                                                                                                                                                                                                                                                                                                                                                                                
  Subgroup: Liver Cancer Study Group of Japan stage II HCC              Favor hepatic resection (significant).                                                                                                                                                                                                                                                                                                                                                                
  Subgroup: Liver Cancer Study Group of Japan stage III HCC             Favor hepatic resection (significant).                                                                                                                                                                                                                                                                                                                                                                
  Schumacher, Ann Hepatol (2010)                                        Full text                                Canada         Retrospective cohort study                                                     1996.1-2006.12    NA                                                                                                      Unselected HCC                                                                                                                       NA.
  Sotiropoulos, Dig Dis Sci (2009)                                      Full text                                Germany        Retrospective cohort study                                                     1998.4-2007.5     Median (range):15.3 (0.2-144) months                                                                    HCC with cirrhosis and no prior tumor treatments                                                                                     Statistically similar.
  Toro, BMC Surg (2014)                                                 Full text                                Italy          Retrospective cohort study                                                     2002.1-2012.12    NA                                                                                                      HCC aged \>18 years, Child-Pugh class A or B                                                                                         NA.
  Ueno, J Hepatobiliary Pancreat Surg (2002)                            Full text                                Japan          Prospective cohort study                                                       1990.1-1998.10    NA                                                                                                      Total: HCC; Child class B and C cirrhosis without lymph node or distant metastasis                                                   Favor hepatic resection (significant).
  Subgroup: Prognostic score = 0                                        Favor hepatic resection (significant).                                                                                                                                                                                                                                                                                                                                                                
  Subgroup: Prognostic score = 1-2                                      Favor hepatic resection (significant).                                                                                                                                                                                                                                                                                                                                                                
  Subgroup: Prognostic score = 3                                        Statistically similar.                                                                                                                                                                                                                                                                                                                                                                                
  Utsunomiya, Ann Surg (2014)                                           Full text                                Japan          Prospective cohort study                                                       2000.1-2005.12    Mean:1.9±1.6 years in resection group;1.5±1.4 years in TACE group                                       Non-HBV and non-HCV HCC                                                                                                              Favor hepatic resection (significant).
  Wang, Academic Journal of Second Military Medical University (2012)   Full text                                China          Propensity score analysis                                                      2003-2011         NA                                                                                                      Early-stage HCC                                                                                                                      Favor hepatic resection (significant).
  Wang, Dig Liver Dis (2013)                                            Full text                                China Taiwan   Retrospective cohort study                                                     2003-2008         NA                                                                                                      BCLC stage C; naïve HCC; ECOG score ≤2 and Child-Pugh class A                                                                        Favor hepatic resection (significant).
  Worns, Scand J Gastroenterol (2012)                                   Full text                                Germany        Retrospective cohort study                                                     1997.1-2009.12    NA                                                                                                      HCC in non-cirrhotic liver                                                                                                           Favor hepatic resection (significant).
  Yamagiwa, J Gastroenterol Hepatol (2008)                              Full text                                Japan          Retrospective cohort study                                                     1995.1-2004.12    Median:1008 days in resection group;609 days in TACE group                                              Unselected HCC                                                                                                                       Favor hepatic resection (significant).
  Yang, Radiology (2014)                                                Full text                                South Korea    Retrospective cohort study[\*](#tfn-001){ref-type="table-fn"}                  2005.1-2006.12    NA                                                                                                      HCC ≤3 cm in diameter, no vascular invasion, single nodule                                                                           Favor hepatic resection (significant).
  Ye, World J Gastroenterol (2014)                                      Full text                                China          Retrospective cohort study                                                     2007-2009         NA                                                                                                      HCC with PVTT                                                                                                                        Favor hepatic resection (significant).
  Yin, J Hepatol (2014)                                                 Full text                                China          Randomized controlled trial                                                    2008.11-2010.9    Median (95%CI):33.3 (28.1-53.8) months in surgery group;13.5 (9.5-18.4) months in TACE group            Resectable multiple HCC outside of Milan criteria                                                                                    Favor hepatic resection (significant).
  Zhang, J Surg Res (2014)                                              Full text                                China          Retrospective cohort study                                                     2005.1-2010.3     Median (range):28 (3-84) months in all patients                                                         Total: HCC; multiple tumors involving both lobes of the liver                                                                        Favor hepatic resection (significant).
  Subgroup: BCLC stage A                                                Favor hepatic resection (significant).                                                                                                                                                                                                                                                                                                                                                                
  Subgroup: BCLC stage B                                                Favor hepatic resection (significant).                                                                                                                                                                                                                                                                                                                                                                
  Subgroup: BCLC stage C                                                Favor hepatic resection (significant).                                                                                                                                                                                                                                                                                                                                                                
  Zhong, Ann Surg (2014)                                                Full text                                China          Propensity score analysis                                                      2000.1-2007.12    Median (range):31.2 (1-120.3) months in the overall analysis[^\#^](#tfn-002){ref-type="table-fn"}       BCLC stage B/C HCC                                                                                                                   Favor hepatic resection (significant).

**Abbreviations:** BCLC, Barcelona Clinic Liver Cancer; HCC, hepatocellular carcinoma; NA, not available; PVTT, portal vein tumor thrombus; UICC, Union International Centre Cancer; VISUM, Vienna survival model.

Notes:

data in propensity score analysis was not collected due to the absence of relevant data.

the follow-up length was not available in the propensity score analysis.

Meta-analysis {#s2_2}
-------------

Four of 50 papers were not included in the meta-analysis, because they reported only the survival times, but not the survival rates or Kaplan-Meier curves \[[@R17], [@R25], [@R32], [@R37]\]. The remaining 46 papers were included in the meta-analysis.

Overall meta-analysis {#s2_3}
---------------------

The overall meta-analysis demonstrated a statistically significantly higher overall survival in hepatic resection group than in TACE group (HR=0.60, 95%CI=0.55-0.66, P\<0.00001) (Figure [2](#F2){ref-type="fig"}). The heterogeneity was statistically significant (P\<0.00001; I^2^=84%). Funnel plots demonstrated that not all studies laid within 95%CI ([Supplementary Figure 1](#SD1){ref-type="supplementary-material"}).

![The overall meta-analysis comparing the overall survival between HCC patients undergoing hepatic resection and TACE](oncotarget-06-18715-g002){#F2}

Additionally, the meta-analyses demonstrated that 1-, 3-, and 5-year survival rates were statistically significantly higher in hepatic resection group than in TACE group (Table [2](#T2){ref-type="table"}). There were statistically significant heterogeneities in all of the 3 meta-analyses.

###### Comparisons of 1-, 3,- and 5-year survival between hepatic resection and TACE groups: Results of meta-analyses

  Variables                                  No. included studies   Hepatic resection group   TACE group   Effect size   Heterogeneity                                         
  ------------------------------------------ ---------------------- ------------------------- ------------ ------------- --------------- ------------------- ----------- ----- -----------
  ***All patients***                                                                                                                                                           
  1-year survival                            41                     6879                      5689         6149          4279            1.82 (1.56-2.14)    \<0.00001   50%   0.0001
  3-year survival                            41                     7392                      4778         6719          2542            3.09 (2.60-3.67)    \<0.00001   70%   \<0.00001
  5-year survival                            32                     6551                      3562         5710          1359            3.48 (2.83-4.27)    \<0.00001   68%   \<0.00001
  ***Within BCLC stage A***                                                                                                                                                    
  1-year survival                            10                     975                       815          859           681             1.38 (1.00-1.91)    0.05        16%   0.3
  3-year survival                            10                     975                       586          859           398             1.92 (1.44-2.57)    \<0.0001    36%   0.12
  5-year survival                            9                      856                       434          740           232             2.55 (1.61-4.06)    \<0.0001    68%   0.002
  ***Beyond BCLC stage A***                                                                                                                                                    
  1-year survival                            16                     1827                      1354         2346          1422            2.06 (1.57-2.71)    \<0.00001   64%   0.0002
  3-year survival                            15                     1789                      940          2201          659             3.51 (2.45-5.02)    \<0.00001   77%   \<0.00001
  5-year survival                            8                      1329                      565          1723          379             2.89 (2.02-4.13)    \<0.00001   66%   0.004
  ***BCLC stage B alone***                                                                                                                                                     
  1-year survival                            3                      561                       474          608           472             2.38 (0.64-8.86)    0.2         91%   \<0.0001
  3-year survival                            3                      561                       378          608           326             4.66 (1.01-21.5)    0.05        88%   0.0002
  5-year survival                            1                      433                       265          490           221             1.92 (1.48-2.50)    \<0.00001   NA    NA
  ***PVTT***                                                                                                                                                                   
  1-year survival                            5                      447                       227          714           277             1.73 (1.17-2.57)    0.006       37%   0.17
  3-year survival                            4                      440                       129          676           90              2.72 (1.59-4.66)    0.0003      41%   0.17
  5-year survival                            2                      309                       86           510           40              7.34 (0.79-68.16)   0.08        88%   0.004
  ***Moderate- and high-quality studies***                                                                                                                                     
  1-year survival                            15                     2097                      1612         2369          1537            1.95 (1.50-2.52)    \<0.00001   64%   0.0004
  3-year survival                            16                     2134                      1152         2402          792             3.04 (2.18-4.23)    \<0.00001   78%   \<0.00001
  5-year survival                            10                     1631                      732          1930          479             2.82 (1.99-4.00)    \<0.00001   72%   0.0002
  ***Studies published after 2005***                                                                                                                                           
  1-year survival                            34                     6385                      5296         5688          3923            1.90 (1.61-2.23)    \<0.00001   51%   0.0002
  3-year survival                            33                     6492                      4191         5573          2150            3.11 (2.58-3.74)    \<0.00001   68%   \<0.00001
  5-year survival                            25                     5690                      3166         4668          1161            3.62 (2.85-4.61)    \<0.00001   71%   \<0.00001

Subgroup analysis in patients with different BCLC stages {#s2_4}
--------------------------------------------------------

In HCC patients within the BCLC stages 0 and A, the subgroup meta-analysis demonstrated a statistically significantly higher overall survival in hepatic resection group than in TACE group (HR=0.72, 95%CI=0.64-0.80, P\<0.00001) (Figure [3](#F3){ref-type="fig"}). The heterogeneity was not statistically significant (P=0.92; I^2^=0%). Funnel plots demonstrated that all studies laid within 95%CI ([Supplementary Figure 2](#SD1){ref-type="supplementary-material"}).
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Additionally, the meta-analyses demonstrated that 1-, 3-, and 5-year survival rates were statistically significantly higher in hepatic resection group than in TACE group (Table [2](#T2){ref-type="table"}). There was a statistically significant heterogeneity in the meta-analysis of 5-year survival rate, but not in those of 1- and 3-year survival rates.

In HCC patients beyond the BCLC stage A, the subgroup meta-analysis demonstrated a statistically significantly higher overall survival in hepatic resection group than in TACE group (HR=0.60, 95%CI=0.51-0.69, P\<0.00001) (Figure [3](#F3){ref-type="fig"}). The heterogeneity was statistically significant (P\<0.00001; I^2^=83%). Funnel plots demonstrated that not all studies laid within 95%CI ([Supplementary Figure 3](#SD1){ref-type="supplementary-material"}).

Additionally, the meta-analyses demonstrated that 1-, 3-, and 5-year survival rates were statistically significantly higher in hepatic resection group than in TACE group (Table [2](#T2){ref-type="table"}). There were statistically significant heterogeneities in all of the three meta-analyses.

There was a statistically significant subgroup difference (P\<0.00001; I^2^=75%).

Subgroup analysis in patients with BCLC stage B alone {#s2_6}
-----------------------------------------------------

In HCC patients with BCLC stage B alone, the subgroup meta-analysis demonstrated a statistically significantly higher overall survival in hepatic resection group than in TACE group (HR=0.48, 95%CI=0.25-0.90, P=0.02) (Figure [4](#F4){ref-type="fig"}). The heterogeneity was statistically significant (P\<0.00001; I^2^=92%). Funnel plots demonstrated that not all studies laid within 95%CI ([Supplementary Figure 4](#SD1){ref-type="supplementary-material"}).
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Additionally, the meta-analyses demonstrated that 1-year survival rate was statistically similar between the two groups, but 3- and 5-year survival rates were statistically significantly higher in hepatic resection group than in TACE group (Table [2](#T2){ref-type="table"}). There were statistically significant heterogeneities in the meta-analyses of 1- and 3-year survival rates. The heterogeneity could not be evaluated in the meta-analysis of 5-year survival rate.

Subgroup analysis in patients with PVTT {#s2_7}
---------------------------------------

In HCC patients with PVTT, the subgroup meta-analysis demonstrated a statistically significantly higher overall survival in hepatic resection group than in TACE group (HR=0.78, 95%CI=0.68-0.91, P=0.0009) (Figure [5](#F5){ref-type="fig"}). The heterogeneity was statistically significant (P=0.06; I^2^=56%). Funnel plots demonstrated that not all studies laid within 95%CI ([Supplementary Figure 5](#SD1){ref-type="supplementary-material"}).
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Additionally, the meta-analyses demonstrated that 1- and 3-year survival rates were statistically significantly higher in hepatic resection group than in TACE group, but 5-year survival rate was statistically similar between the two groups (Table [2](#T2){ref-type="table"}). There was a statistically significant heterogeneity in the meta-analysis of 5-year survival rate, but not in those of 1- and 3-year survival rates.

Sensitivity analyses in moderate- and high-quality studies {#s2_8}
----------------------------------------------------------

In 16 moderate- and high-quality studies, the sensitivity analysis demonstrated a statistically significantly higher overall survival in hepatic resection group than in TACE group (HR=0.62, 95%CI=0.53-0.71, P\<0.00001) (Figure [6](#F6){ref-type="fig"}). The heterogeneity was statistically significant (P\<0.00001; I^2^=83%). Funnel plots demonstrated that not all studies laid within 95%CI ([Supplementary Figure 6](#SD1){ref-type="supplementary-material"}).
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Additionally, the meta-analyses demonstrated that 1-, 3-, and 5-year survival rates were statistically significantly higher in hepatic resection group than in TACE group (Table [2](#T2){ref-type="table"}). There were statistically significant heterogeneities in all of the 3 meta-analyses.

Sensitivity analyses in studies published after 2005 {#s2_9}
----------------------------------------------------

In 37 studies published after 2005, the sensitivity analysis demonstrated a statistically significantly higher overall survival in hepatic resection group than in TACE group (HR=0.59, 95%CI=0.53-0.66, P\<0.00001) (Figure [7](#F7){ref-type="fig"}). The heterogeneity was statistically significant (P\<0.00001; I^2^=86%). Funnel plots demonstrated that not all studies laid within 95%CI ([Supplementary Figure 7](#SD1){ref-type="supplementary-material"}).

![Sensitivity analysis in studies published after 2005](oncotarget-06-18715-g007){#F7}

Additionally, the meta-analyses demonstrated that 1-, 3-, and 5-year survival rates were statistically significantly higher in hepatic resection group than in TACE group (Table [2](#T2){ref-type="table"}). There were statistically significant heterogeneities in all of the 3 meta-analyses.

DISCUSSION {#s3}
==========

In theory, the BCLC staging system needs to be persistently updated with the dramatic improvement in the understanding of HCC and the invention of novel therapeutic modalities for HCC. Accumulated evidence suggests that the optimal treatment modality of HCC in the BCLC stage B may be further refined. In the present systematic review, we collected the comparative data regarding the overall survival in HCC patients undergoing hepatic resection and TACE. The overall meta-analysis demonstrated a statistically significant survival benefit of hepatic resection over TACE. In addition, considering the potential bias of patient selection, we performed several subgroup meta-analyses. All of them confirmed statistically significant survival benefits of hepatic resection over TACE.

At present, the curative treatment options of HCC mainly include liver transplantation (LT), hepatic resection, and radiofrequency ablation (RFA). Although LT is obviously superior to hepatic resection for the complete removal of tumor tissues, it is largely restricted by the scarcity of liver donors. On the other hand, hepatic resection appears to be superior to RFA for the improvement of overall survival and recurrence-free survival in HCC within the Milan criteria \[[@R56]\]. In clinical practices, hepatic resection is often regarded as the primary choice of therapy for early stage HCC, if the lesion is single, hepatic function is well-preserved, and portal hypertension is not severe. Under this circumstance, the results of our subgroup meta-analysis that hepatic resection could achieve a significantly better survival than TACE in HCC within the BCLC stage A were in line with our expectations.

The non-curative treatment options of HCC mainly include TACE and sorafenib. TACE is the first-line treatment option of HCC in the BCLC stage B. This recommendation is primarily attributed to the survival benefits of TACE over conservative or suboptimal treatments \[[@R57]\]. But we are not sure about whether TACE surpasses other active treatments for the improvement of overall survival. Our subgroup meta-analyses suggested that the survival was statistically significantly better in HCC patients beyond the BCLC stage A undergoing hepatic resection than in those undergoing TACE. Thus, hepatic resection might be also considered in selected HCC cases in the BCLC stage B.

After our study was registered, Kapitanov and colleagues published a similar meta-analysis to compare the short- and long-term results of hepatic resection versus TACE in HCC patients with cirrhosis \[[@R58]\]. They also concluded that the survival at 1 and 3 years was significantly better in patients treated with surgery than in those treated with TACE. Compared with their study, our systematic review and meta-analysis had several strengths. First, the selection of target population was broader and the number of included studies was larger. Thus, we were permitted to conduct more subgroup meta-analyses according to the study and patient characteristics. Second, the study quality was strictly assessed. Thus, we could readily understand the grade of current evidence. Third, the duplicate data were excluded, thereby avoiding the inflation of relevant information \[[@R59]\]. In the meta-analysis by Kapitanov et al., two papers by Zhong et al. were included. However, they reported the overlapping data. In the first paper, 392 HCC patients in the BCLC stage B were enrolled between January 2000 and November 2007 \[[@R60]\]; and in the second paper, 860 HCC patients in the BCLC stages B and C were enrolled between January 2000 and November 2007 \[[@R55]\]. By comparison, the first paper with a smaller sample size was excluded from our meta-analysis. Indeed, four other papers conducted by the same study team were also excluded from our meta-analysis \[[@R61]-[@R64]\].

The limitations of our meta-analysis should be clearly emphasized. First, only one included study was a randomized controlled trial. Additionally, a majority of included studies were of low quality. Certainly, we conducted a subgroup meta-analysis of moderate- and high-quality studies to confirm the reliability of our findings. Second, the heterogeneity among studies was statistically significant in all but one meta-analysis of HCC cases within the BCLC stage A. We employed a random-effect model to produce a relatively conservative estimate. Third, the publication bias was statistically significant in a majority of meta-analyses, despite three major English-language databases were searched. Fourth, the overall survival was the sole outcome observed in our study. Thus, we could not capture the other advantages or disadvantages of hepatic resection versus TACE. However, it should be noted that the overall survival was the most important endpoint to measure the therapeutic effectiveness in HCC \[[@R65]\]. By contrast, the time to recurrence, progression-free survival, and disease-free survival were the secondary endpoints. We could hardly translate the improvements in these secondary endpoints into the clinical practice recommendations.

In conclusions, hepatic resection might provide a better overall survival than TACE in HCC beyond the BCLC stage A. However, we should acknowledge that the current evidence is of low-quality. Considering that the drawbacks of study designs potentially lead to the selection biases, more well-designed randomized controlled trials should be warranted to compare the survival benefit of hepatic resection versus TACE in such patients.

METERIALS AND METHODS {#s4}
=====================

This work was registered with PROSPERO on December 19, 2014 (registration number: CRD42014015618).

Search strategy {#s4_1}
---------------

The PubMed, EMBASE, and Cochrane Library databases were searched. Search items were as follows: ("Hepatectomy" OR "Liver resection" OR "Hepatic resection" OR "Liver surgery" OR "Hepatic surgery") AND ("TACE" OR "transarterial chemoembolization") AND ("HCC" OR "hepatocellular carcinoma" OR "hepatic carcinoma"). The last search was performed on December 18, 2014. Relevant literatures were also manually searched.

Study selection {#s4_2}
---------------

Only clinical studies including more than 10 patients were considered in the systematic review. Accordingly, duplicate papers among databases, redundant publications, narrative or systematic reviews, study protocols, comments, experimental studies, and case reports were excluded. If two or more papers by the same study team had the overlapping data, only one paper with more adequate data and/or a longer enrollment period would be included.

The inclusion criteria should be as follows.

1.  *Participants:* patients with HCC.

2.  *Interventions:* hepatic resection and TACE as initial treatment modalities.

3.  *Comparisons:* hepatic resection versus TACE.

4.  *Outcomes:* overall survival.

The exclusion criteria should be as follows.

1.  Non-HCC.

2.  Hepatic metastases.

3.  Mixed malignancies.

4.  Non-comparative studies.

5.  No comparison between hepatic resection versus TACE.

6.  TACE before and after hepatic resection.

7.  Comparison between hepatic resection versus TACE for recurrent HCC.

8.  Comparison between hepatic resection versus TACE for spontaneous rupture of HCC.

9.  No separate data in the hepatic resection or TACE group.

10. No detailed data regarding the survival rate in the hepatic resection or TACE group.

11. No detailed data regarding the number of observed patients in the hepatic resection or TACE group.

Notably, the major reason for exclusion of studies including patients with recurrent HCC and spontaneous rupture of HCC was the discrepancy in the treatment selection and outcomes among them.

Data extraction {#s4_3}
---------------

The following data were extracted: the first author, publication year, publication form, region, enrollment period, study design, study population, follow-up time, inclusion and exclusion criteria, number of HCC cases, treatment selection, survival rate, survival times, and Kaplan-Meier curve analysis with log-rank test. If the propensity score matching analysis was performed, we just collected the survival data after the propensity score matching analyses. If both survival rates and Kaplan-Meier curves were presented, only the survival rates would be collected. If only Kaplan-Meier curves were presented, we extracted the cumulative 1-, 3-, and 5-year survival rates by using the Distance Tool in the Measurements menu of Foxit PDF Reader software version 5.4.4.1023 (Foxit Cooperation, California, USA). This software was freely downloaded.

Study quality {#s4_4}
-------------

Because both retrospective/prospective observational studies and randomized controlled trials were included in the present systematic review, we could not employ a single scale to evaluate the quality of all included studies. More importantly, because our study was designed to compare the overall survival between patients undergoing hepatic resection and those undergoing TACE, the study quality assessment should primarily focus on the comparability of patient characteristics between the two groups. According to the Newcastle-Ottawa scale and major prognostic factors of HCC \[[@R66]\], we developed the following 9 questions that were more specific to the study quality assessment in the present systematic review.

1.  Were the patients consecutively enrolled and prospectively followed?

2.  Was the age statistically similar between the two groups?

3.  Was the gender statistically similar between the two groups?

4.  Was the Child-Pugh score/class or MELD score statistically similar between the two groups?

5.  Were the diameter and number of tumor statistically similar between the two groups?

6.  Was the BCLC stage or other HCC stage statistically similar between the two groups?

7.  Were the criteria for treatment selection homogeneous between the two groups?

8.  Was the follow-up time clearly reported?

9.  Was the proportion of patients lost to follow-up less than 20%?

If the answers to 7-9 questions were "Yes", the study would be considered to be of high quality. If the answers to 4-6 questions were "Yes", the study would be considered to be of moderate quality. Otherwise, it would be considered to be of poor quality.

Meta analysis {#s4_5}
-------------

Only a minority of included studies clearly reported the hazard ratios (HRs) for the overall survival in HCC patients with hepatic resection versus TACE. Therefore, we calculated ln \[HR\] with standard error by using the calculation sheets which were developed by Matthew Sydes and Jayne Tierney \[[@R67]\]. The survival rates at different time points were entered into the calculation sheet of "(2a) curve data". Accordingly, a curve was produced in the calculation sheet of "(2b) curve copy", and ln\[HR\] and se(ln\[HR\]) could be available in the calculation sheet of "(4) output information". Then, HRs with 95% confidence intervals (CIs) were pooled by using a random-effects model. Additionally, to provide the survival data in detail, we compared the 1-, 3-, and 5-year survival rates between HCC patients with hepatic resection versus TACE. The odd ratios (ORs) with 95% CIs were pooled by using a random random-effects model. In these meta-analyses, a P value of \<0.05 was considered statistically significant. Heterogeneity between studies was assessed by using the I^2^ statistic (I^2^\> 50% was considered as having substantial heterogeneity) and the Chi-square test (P\<0.10 was considered to represent significant statistical heterogeneity). Funnel plots were performed to evaluate the publication bias. Subgroup meta-analyses were performed according to the BCLC stages (within versus beyond BCLC stage A). Subgroup difference between the two groups was evaluated by using the I^2^ statistic (I^2^\> 50% was considered as having statistically significant difference) and the Chi-square test (P\<0.10 was considered to represent statistically significant difference). Subgroup meta-analyses were also performed in patients with BCLC stage B alone and in those with portal vein tumor thrombus (PVTT). Sensitivity analyses were performed in moderate- and high-quality studies and studies published after 2005. All meta-analyses were conducted by using the statistical package Review Manager version 5.1.6 (Copenhagen, The Nordic Cochrane Center, The Cochrane Collaboration, 2011).
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